#IKCS24 - Twitter Hashtag

over 1 year ago

🚨#IKCS24 Proceedings is out! https://t.co/0XDpUcnbMi 📕flipbook: https://t.co/f179qGvWzB 👉25 years of #ICKS24 - Special editorials by @brian_rini @DrTHut @salvolarosa @KidneyCancer

KidneyCancerJ's tweet photo. 🚨#IKCS24 Proceedings is out!
https://t.co/0XDpUcnbMi

📕flipbook: https://t.co/f179qGvWzB

👉25 years of #ICKS24 - Special editorials by @brian_rini @DrTHut @salvolarosa @KidneyCancer https://t.co/jgvVUmk8XN

0

13

7

0

1K

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

almost 2 years ago

@RCCadvocate Dena Battle eloquent in showing most recent @kcCURE survey data — high burden of disease — 52% pts spend several HOURS per day thinking about cancer. While OS is gold standard, we need to think about pts living, not merely surviving. @KidneyCancer #IKCS24

TiansterZhang's tweet photo. @RCCadvocate Dena Battle eloquent in showing most recent @kcCURE survey data — high burden of disease — 52% pts spend several HOURS per day thinking about cancer. While OS is gold standard, we need to think about pts living, not merely surviving. @KidneyCancer #IKCS24 https://t.co/1xnvR8kcl3

0

27

13

0

3K

Katy Beckermann

@katy_beckermann

almost 2 years ago

Missing my #IKCS24 colleagues but pumped for #SITC24! 🧬✨ Learning about TIL states from Rafi Ahmed’s keynote: stem-like, transitory, & exhausted. Always learning, always inspired! 💪 #Immunotherapy #CancerResearch

katy_beckermann's tweet photo. Missing my #IKCS24 colleagues but pumped for #SITC24! 🧬✨ Learning about TIL states from Rafi Ahmed’s keynote: stem-like, transitory, & exhausted. Always learning, always inspired! 💪 #Immunotherapy #CancerResearch https://t.co/GVbSuFMgkR

2

20

3

1

1K

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

almost 2 years ago

Great to see @UTSW_RadOnc @Raquib_Hannan discussing SAbR for IVC thrombi and primary #kidneycancer! #IKCS24 @KidneyCancer

QianJanieQin @QianJanieQin

almost 2 years ago

@UTSW_RadOnc Dr. @Raquib_Hannan- #SAbR and adaptive SAbR/#PULSAR are changing how we treat locally advanced/unresectable RCC, offering effective palpation and locally control with more to come #IKCSNA24 @KidneyCancer @TiansterZhang @utswcancer

QianJanieQin's tweet photo. @UTSW_RadOnc Dr. @Raquib_Hannan- #SAbR and adaptive SAbR/#PULSAR are changing how we treat locally advanced/unresectable RCC, offering effective palpation and locally control with more to come #IKCSNA24 @KidneyCancer @TiansterZhang @utswcancer https://t.co/gjOlx6DE20

1

11

6

1

2K

1

7

0

723

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

almost 2 years ago

Fantastic planning from @bergsa83 #JodiMaranchie for #IKCS24 @KidneyCancer!

Moshe Ornstein MD @MosheOrnsteinMD

almost 2 years ago

Kicking off favorite meeting of the year #IKCSNA24 with chairs @bergsa83 and Dr. J Maranchie @KidneyCancer

1

19

4

1

2K

0

11

1

0

975

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

almost 2 years ago

Great think tank on biomarkers today @KidneyCancer #IKCS24! Thanks @d_shapiro1 @pearldaily for keeping us on task!

Matt Campbell MD, MS

@DocMattCampbell

almost 2 years ago

Fantastic Think Tank to start #IKCSNA24 on Biomarker development and risk stratification in kidney cancer. Great job by our moderators @d_shapiro1 @pearldaily

DocMattCampbell's tweet photo. Fantastic Think Tank to start #IKCSNA24 on Biomarker development and risk stratification in kidney cancer. Great job by our moderators @d_shapiro1 @pearldaily https://t.co/AFexFSI2F3

0

18

1

2K

1

12

1

0

4K

Jose Tapia @TapiaJC1

over 2 years ago

Quality of life in Spain is different #IKCS24 Not sure which scale will capture this 😂. @_SEOM @myESMO

0

6

0

483

Tom Powles

@tompowles1

over 2 years ago

Subset data from belzutifan vs everolimus study in pretreated clear cell RCC #IKCS24. We thought belzutifan would be better in good risk disease and with fewer lines of therapy but these data suggest that’s not the case. Biomakers will need to be biological rather than clinical

tompowles1's tweet photo. Subset data from belzutifan vs everolimus study in pretreated clear cell RCC #IKCS24. We thought belzutifan would be better in good risk disease and with fewer lines of therapy but these data suggest that’s not the case. Biomakers will need to be biological rather than clinical https://t.co/Zja84EdmrY

0

61

19

13

5K

Tom Powles

@tompowles1

over 2 years ago

Updated data with lenvatinib and Pembrolizumab in 158 1st line advanced non-clear cell renal cancer #ikcs24. 8 mnths extra FU. RR= 50% seems higher than sunitinib. 18 month mPFS and 80% 12 month OS also looks ⬆️, but randomised trials such as SAMETA and XL92/nivo remain important

tompowles1's tweet photo. Updated data with lenvatinib and Pembrolizumab in 158 1st line advanced non-clear cell renal cancer #ikcs24. 8 mnths extra FU. RR= 50% seems higher than sunitinib. 18 month mPFS and 80% 12 month OS also looks ⬆️, but randomised trials such as SAMETA and XL92/nivo remain important https://t.co/T2WOz1LfX3

1

95

31

13

10K

Jose Tapia @TapiaJC1

over 2 years ago

Wishes for the future from patients perspective. Two heart touching stories have been shared today at #IKCS24. Stories which encourage the idea that clinical trials bring hope when options are limited. Cancer centres and oncologists should take this into consideration.